Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mycoplasma bovis vaccine and methods of reducing pneumonia in animals

A technology of Mycoplasma bovis and vaccine, which is used in the preparation of Mycoplasma bovis vaccines and kits, the treatment or prevention of diseases or illnesses caused by Mycoplasma bovis infection, and the field of combined vaccines, which can solve problems such as no vaccine available.

Inactive Publication Date: 2004-08-18
PFIZER PRODS ETAT DE CONNECTICUT
View PDF1 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Antibiotic treatment is often used to reduce mortality, as no fully licensed vaccine is currently available

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
  • Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
  • Mycoplasma bovis vaccine and methods of reducing pneumonia in animals

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Materials and Methods

[0064] animal

[0065] Healthy crossbred heifers of approximately 14 days of age were obtained for immunization. Calves were acclimatized for 7 days before starting the study. All calves received daily concentrated, drug-free food free of any known contaminants or pesticides, and calves had free access to water.

[0066] vaccine

[0067] The bacterin contains BEI-inactivated whole-cell M. bovis bacterin at the appropriate concentration for each dose. In addition, each vaccine formulation contains phosphate-buffered saline (PBS) and appropriate adjuvants. Placebo contained PBS or PBS and oil-in-water adjuvant.

[0068] attack method

[0069] Give each calf 10 or 12 ml of a fresh M. bovis culture [approximately 1 x 10 8 ~1×10 10 colony forming unit (CFU / ml)]. The counts (CFU / ml) of the challenge inoculum were determined shortly after completion of each experimental challenge.

[0070] Experimental procedure

[0071] U...

Embodiment 2

[0083] In this example, the efficacy of the M. bovis bacterin was assessed in young calves. Twenty-four healthy crossbred calves were randomly assigned according to age.

[0084] Animals were immunized by subcutaneous route on day 0 (left neck) and day 21 (right neck) with 2 ml of vaccine or placebo. The experimental treatment groups and the vaccines used are shown in Table 1.

[0085] Table 1

[0086] treatment group

[0087] Calves were challenged 3 weeks after the second immunization as described above. Each calf received 10 ml of fresh M. bovis culture by intranasal route on 3 consecutive days.

[0088] The number of inoculum per challenge (CFU / ml) was determined within 1 hour after completion of the M. bovis experimental challenge. The results are shown in Table 2.

[0089] challenge inoculum

[0090]All animals were weighed 1 day before challenge, 7 days after challenge, 14 days after challenge and approximately 3 weeks af...

Embodiment 3

[0108] In this example, the efficacy of various M. bovis bacterins was assessed in young calves. Fifty-eight healthy crossbreed calves were randomly assigned by age.

[0109] Animals were immunized by subcutaneous route on day 0 (left neck) and day 21 (right neck) with 2 ml of the appropriate vaccine or placebo. The experimental treatment groups and the vaccines used are shown in Table 1.

[0110] Table 1

[0111] treatment group

[0112] Calves were challenged 3 weeks after the second immunization as described above. Each calf received 12 ml of fresh M. bovis culture by intranasal route on 3 consecutive days.

[0113] Viable counts (CFU / ml) of each challenge inoculum were determined within 1 hour after completion of the M. bovis experimental challenge. The results are shown in Table 2.

[0114] challenge inoculum

[0115] All animals were weighed 1 day before challenge, 7 days after challenge, 14 days after challenge and appr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to Mycoplasma bovis vaccines and methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma bovis by administering to the animal an effective amount of a Mycoplasma bovis vaccine. The Mycoplasma bovis vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The Mycoplasma bovis vaccine administered in accordance with the present can be synthesized or recombinantly produced. The invention also relates to combination vaccines, methods of preparing Mycoplasma bovis vaccines and kits.

Description

field of invention [0001] The present invention relates to Mycoplasma bovis vaccine formulations and methods for treating or preventing diseases or conditions caused by Mycoplasma bovis infection in animals. The M. bovis vaccine may be a whole or partial cell inactivated or modified live preparation, a subunit vaccine or a nucleic acid or DNA vaccine. The M. bovis vaccine administered according to the invention may be produced synthetically or recombinantly. The invention also relates to combination vaccines, methods for preparing M. bovis vaccines and kits. Background of the invention [0002] Mycoplasma bovis is an important global bovine pathogen in domestic or intensively raised beef cattle and dairy cattle. The most frequently reported clinical phenomenon is bovine pneumonia, often accompanied by arthritis, also known as pneumonia-arthritis syndrome. Its pathogenic role has also been implicated in mastitis, otitis and reproductive diseases or cond...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K39/02A61K39/12A61P31/04C12N1/20C12N1/36
CPCA61K2039/55577A61K2039/521A61K2039/552A61K39/0241C12N1/36A61P31/04A61P31/12A61K39/02
Inventor P·L·凯奇D·R·麦克加文R·J·扬西
Owner PFIZER PRODS ETAT DE CONNECTICUT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com